Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2139925 | Leukemia Research | 2006 | 4 Pages |
Abstract
Imatinib mesylate, an inhibitor of BCR/ABL tyrosine kinase, has remarkable activity in chronic myeloid leukemia resulting in an 87% major cytogenetic response. We describe a woman who failed to achieve any cytogenetic response after 2.5 years of imatinib, 400 mg daily. When daily sargramostim (GM-CSF) 100 μg/m2 was added, cytogenetic studies revealed a gradual increase in percentage of normal cells from start, 4, 9, and 15 months at 0%, 10%, 55%, and 85%, respectively. She became transfusion independent after starting GM-CSF. The addition of GM-CSF to imatinib resulted in a clinical benefit and a major cytogenetic response in this patient.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Rebecca F. Connor, David Hurd, Mark J. Pettenati, Patrick Koty, István Molnár,